nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—KCNH2—Sunitinib—kidney cancer	0.085	0.121	CbGbCtD
Tolterodine—CYP2D6—Temsirolimus—kidney cancer	0.081	0.115	CbGbCtD
Tolterodine—CYP3A4—Everolimus—kidney cancer	0.0762	0.109	CbGbCtD
Tolterodine—CYP3A4—Temsirolimus—kidney cancer	0.0515	0.0734	CbGbCtD
Tolterodine—CYP2C9—Capecitabine—kidney cancer	0.0485	0.0691	CbGbCtD
Tolterodine—CYP2D6—Pazopanib—kidney cancer	0.0425	0.0606	CbGbCtD
Tolterodine—CYP2C19—Sorafenib—kidney cancer	0.0325	0.0463	CbGbCtD
Tolterodine—CYP2C9—Paclitaxel—kidney cancer	0.0304	0.0433	CbGbCtD
Tolterodine—CYP2D6—Erlotinib—kidney cancer	0.0303	0.0433	CbGbCtD
Tolterodine—CYP3A4—Pazopanib—kidney cancer	0.027	0.0385	CbGbCtD
Tolterodine—CYP2C9—Sorafenib—kidney cancer	0.027	0.0385	CbGbCtD
Tolterodine—CYP2D6—Sorafenib—kidney cancer	0.0247	0.0352	CbGbCtD
Tolterodine—CYP2D6—Vinblastine—kidney cancer	0.0244	0.0347	CbGbCtD
Tolterodine—CYP3A4—Erlotinib—kidney cancer	0.0193	0.0275	CbGbCtD
Tolterodine—CYP3A4—Paclitaxel—kidney cancer	0.0177	0.0252	CbGbCtD
Tolterodine—CHRM3—ureter—kidney cancer	0.0176	0.425	CbGeAlD
Tolterodine—CYP3A4—Sorafenib—kidney cancer	0.0157	0.0224	CbGbCtD
Tolterodine—CYP3A4—Vinblastine—kidney cancer	0.0155	0.0221	CbGbCtD
Tolterodine—CYP3A4—Vincristine—kidney cancer	0.0152	0.0217	CbGbCtD
Tolterodine—CYP2D6—Doxorubicin—kidney cancer	0.015	0.0213	CbGbCtD
Tolterodine—CYP3A4—Sunitinib—kidney cancer	0.0127	0.0181	CbGbCtD
Tolterodine—CYP3A4—Doxorubicin—kidney cancer	0.00952	0.0136	CbGbCtD
Tolterodine—CYP2C19—urine—kidney cancer	0.00531	0.128	CbGeAlD
Tolterodine—CYP2C9—urine—kidney cancer	0.00412	0.0996	CbGeAlD
Tolterodine—CYP3A4—urine—kidney cancer	0.00314	0.076	CbGeAlD
Tolterodine—CYP2D6—urine—kidney cancer	0.00309	0.0748	CbGeAlD
Tolterodine—CHRM3—renal system—kidney cancer	0.0014	0.0338	CbGeAlD
Tolterodine—CHRM3—kidney—kidney cancer	0.00135	0.0327	CbGeAlD
Tolterodine—KCNH2—renal system—kidney cancer	0.00124	0.03	CbGeAlD
Tolterodine—KCNH2—cardiac atrium—kidney cancer	0.00111	0.0269	CbGeAlD
Tolterodine—Palpitations—Everolimus—kidney cancer	0.00087	0.00383	CcSEcCtD
Tolterodine—Abdominal pain—Temsirolimus—kidney cancer	0.000854	0.00376	CcSEcCtD
Tolterodine—Dry skin—Paclitaxel—kidney cancer	0.00084	0.0037	CcSEcCtD
Tolterodine—Chest pain—Everolimus—kidney cancer	0.000838	0.00369	CcSEcCtD
Tolterodine—Arthralgia—Everolimus—kidney cancer	0.000838	0.00369	CcSEcCtD
Tolterodine—Anxiety—Everolimus—kidney cancer	0.000835	0.00368	CcSEcCtD
Tolterodine—Gastrointestinal pain—Pazopanib—kidney cancer	0.000832	0.00366	CcSEcCtD
Tolterodine—Flushing—Dactinomycin—kidney cancer	0.00083	0.00365	CcSEcCtD
Tolterodine—Dry mouth—Everolimus—kidney cancer	0.000819	0.00361	CcSEcCtD
Tolterodine—Flatulence—Sunitinib—kidney cancer	0.00081	0.00357	CcSEcCtD
Tolterodine—Arthralgia—Erlotinib—kidney cancer	0.000808	0.00356	CcSEcCtD
Tolterodine—Chest pain—Erlotinib—kidney cancer	0.000808	0.00356	CcSEcCtD
Tolterodine—Anxiety—Erlotinib—kidney cancer	0.000806	0.00355	CcSEcCtD
Tolterodine—Abdominal pain—Pazopanib—kidney cancer	0.000804	0.00354	CcSEcCtD
Tolterodine—Oedema—Everolimus—kidney cancer	0.000803	0.00354	CcSEcCtD
Tolterodine—Infection—Everolimus—kidney cancer	0.000798	0.00351	CcSEcCtD
Tolterodine—Hypersensitivity—Temsirolimus—kidney cancer	0.000796	0.0035	CcSEcCtD
Tolterodine—Hallucination—Vincristine—kidney cancer	0.000795	0.0035	CcSEcCtD
Tolterodine—Tachycardia—Everolimus—kidney cancer	0.000784	0.00345	CcSEcCtD
Tolterodine—Angioedema—Sorafenib—kidney cancer	0.000781	0.00344	CcSEcCtD
Tolterodine—Oedema—Erlotinib—kidney cancer	0.000775	0.00341	CcSEcCtD
Tolterodine—Asthenia—Temsirolimus—kidney cancer	0.000775	0.00341	CcSEcCtD
Tolterodine—Infection—Erlotinib—kidney cancer	0.00077	0.00339	CcSEcCtD
Tolterodine—CYP3A4—renal system—kidney cancer	0.000769	0.0186	CbGeAlD
Tolterodine—Bronchitis—Paclitaxel—kidney cancer	0.000762	0.00336	CcSEcCtD
Tolterodine—CYP2D6—renal system—kidney cancer	0.000756	0.0183	CbGeAlD
Tolterodine—Angioedema—Sunitinib—kidney cancer	0.000751	0.00331	CcSEcCtD
Tolterodine—Oedema peripheral—Gemcitabine—kidney cancer	0.000746	0.00329	CcSEcCtD
Tolterodine—CYP3A4—kidney—kidney cancer	0.000743	0.018	CbGeAlD
Tolterodine—Dysuria—Paclitaxel—kidney cancer	0.000741	0.00326	CcSEcCtD
Tolterodine—Diarrhoea—Temsirolimus—kidney cancer	0.000739	0.00325	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Paclitaxel—kidney cancer	0.000737	0.00324	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Everolimus—kidney cancer	0.000732	0.00322	CcSEcCtD
Tolterodine—CYP2D6—kidney—kidney cancer	0.000731	0.0177	CbGeAlD
Tolterodine—Asthenia—Pazopanib—kidney cancer	0.00073	0.00321	CcSEcCtD
Tolterodine—Arthralgia—Sorafenib—kidney cancer	0.000727	0.0032	CcSEcCtD
Tolterodine—Weight increased—Paclitaxel—kidney cancer	0.000721	0.00318	CcSEcCtD
Tolterodine—Urinary retention—Capecitabine—kidney cancer	0.000716	0.00315	CcSEcCtD
Tolterodine—Somnolence—Everolimus—kidney cancer	0.000714	0.00314	CcSEcCtD
Tolterodine—Dizziness—Temsirolimus—kidney cancer	0.000714	0.00314	CcSEcCtD
Tolterodine—Dry mouth—Sorafenib—kidney cancer	0.000711	0.00313	CcSEcCtD
Tolterodine—Dyspepsia—Everolimus—kidney cancer	0.000707	0.00311	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Erlotinib—kidney cancer	0.000706	0.00311	CcSEcCtD
Tolterodine—Arthralgia—Sunitinib—kidney cancer	0.0007	0.00308	CcSEcCtD
Tolterodine—Chest pain—Sunitinib—kidney cancer	0.0007	0.00308	CcSEcCtD
Tolterodine—Anaphylactic shock—Sorafenib—kidney cancer	0.000697	0.00307	CcSEcCtD
Tolterodine—Diarrhoea—Pazopanib—kidney cancer	0.000696	0.00306	CcSEcCtD
Tolterodine—Infection—Sorafenib—kidney cancer	0.000693	0.00305	CcSEcCtD
Tolterodine—Fatigue—Everolimus—kidney cancer	0.000692	0.00305	CcSEcCtD
Tolterodine—Dry skin—Capecitabine—kidney cancer	0.00069	0.00304	CcSEcCtD
Tolterodine—Constipation—Vinblastine—kidney cancer	0.000689	0.00304	CcSEcCtD
Tolterodine—Pain—Vinblastine—kidney cancer	0.000689	0.00304	CcSEcCtD
Tolterodine—Urinary tract infection—Paclitaxel—kidney cancer	0.000687	0.00302	CcSEcCtD
Tolterodine—Pain—Everolimus—kidney cancer	0.000687	0.00302	CcSEcCtD
Tolterodine—Constipation—Everolimus—kidney cancer	0.000687	0.00302	CcSEcCtD
Tolterodine—Dry mouth—Sunitinib—kidney cancer	0.000684	0.00301	CcSEcCtD
Tolterodine—Dyspepsia—Erlotinib—kidney cancer	0.000682	0.003	CcSEcCtD
Tolterodine—Headache—Temsirolimus—kidney cancer	0.000676	0.00298	CcSEcCtD
Tolterodine—Dizziness—Pazopanib—kidney cancer	0.000673	0.00296	CcSEcCtD
Tolterodine—Oedema—Sunitinib—kidney cancer	0.000671	0.00295	CcSEcCtD
Tolterodine—Fatigue—Erlotinib—kidney cancer	0.000668	0.00294	CcSEcCtD
Tolterodine—Infection—Sunitinib—kidney cancer	0.000666	0.00293	CcSEcCtD
Tolterodine—Feeling abnormal—Vinblastine—kidney cancer	0.000664	0.00293	CcSEcCtD
Tolterodine—Sinusitis—Paclitaxel—kidney cancer	0.000663	0.00292	CcSEcCtD
Tolterodine—Constipation—Erlotinib—kidney cancer	0.000663	0.00292	CcSEcCtD
Tolterodine—Pain—Erlotinib—kidney cancer	0.000663	0.00292	CcSEcCtD
Tolterodine—Feeling abnormal—Everolimus—kidney cancer	0.000662	0.00291	CcSEcCtD
Tolterodine—Gastrointestinal pain—Vinblastine—kidney cancer	0.000659	0.0029	CcSEcCtD
Tolterodine—Gastrointestinal pain—Everolimus—kidney cancer	0.000657	0.00289	CcSEcCtD
Tolterodine—Influenza like illness—Doxorubicin—kidney cancer	0.000649	0.00286	CcSEcCtD
Tolterodine—Abdominal pain—Vinblastine—kidney cancer	0.000637	0.00281	CcSEcCtD
Tolterodine—Headache—Pazopanib—kidney cancer	0.000637	0.00281	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.000635	0.0028	CcSEcCtD
Tolterodine—Oedema—Dactinomycin—kidney cancer	0.000635	0.0028	CcSEcCtD
Tolterodine—Abdominal pain—Everolimus—kidney cancer	0.000635	0.0028	CcSEcCtD
Tolterodine—Gastrointestinal pain—Erlotinib—kidney cancer	0.000634	0.00279	CcSEcCtD
Tolterodine—Infection—Dactinomycin—kidney cancer	0.000631	0.00278	CcSEcCtD
Tolterodine—Bronchitis—Capecitabine—kidney cancer	0.000625	0.00275	CcSEcCtD
Tolterodine—Oedema peripheral—Paclitaxel—kidney cancer	0.000625	0.00275	CcSEcCtD
Tolterodine—Vertigo—Vincristine—kidney cancer	0.000625	0.00275	CcSEcCtD
Tolterodine—Dry eye—Doxorubicin—kidney cancer	0.000617	0.00272	CcSEcCtD
Tolterodine—Dyspepsia—Sorafenib—kidney cancer	0.000614	0.0027	CcSEcCtD
Tolterodine—Abdominal pain—Erlotinib—kidney cancer	0.000613	0.0027	CcSEcCtD
Tolterodine—Visual impairment—Paclitaxel—kidney cancer	0.000611	0.00269	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000611	0.00269	CcSEcCtD
Tolterodine—Dysuria—Capecitabine—kidney cancer	0.000608	0.00268	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Capecitabine—kidney cancer	0.000604	0.00266	CcSEcCtD
Tolterodine—Fatigue—Sorafenib—kidney cancer	0.000601	0.00265	CcSEcCtD
Tolterodine—Pain—Sorafenib—kidney cancer	0.000596	0.00262	CcSEcCtD
Tolterodine—Constipation—Sorafenib—kidney cancer	0.000596	0.00262	CcSEcCtD
Tolterodine—Hypersensitivity—Vinblastine—kidney cancer	0.000594	0.00262	CcSEcCtD
Tolterodine—Weight increased—Capecitabine—kidney cancer	0.000592	0.00261	CcSEcCtD
Tolterodine—Hypersensitivity—Everolimus—kidney cancer	0.000592	0.00261	CcSEcCtD
Tolterodine—Dyspepsia—Sunitinib—kidney cancer	0.000591	0.0026	CcSEcCtD
Tolterodine—Flushing—Paclitaxel—kidney cancer	0.000589	0.00259	CcSEcCtD
Tolterodine—Abnormal vision—Doxorubicin—kidney cancer	0.000583	0.00257	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000579	0.00255	CcSEcCtD
Tolterodine—Asthenia—Vinblastine—kidney cancer	0.000578	0.00255	CcSEcCtD
Tolterodine—Fatigue—Sunitinib—kidney cancer	0.000578	0.00255	CcSEcCtD
Tolterodine—Asthenia—Everolimus—kidney cancer	0.000576	0.00254	CcSEcCtD
Tolterodine—Constipation—Sunitinib—kidney cancer	0.000574	0.00253	CcSEcCtD
Tolterodine—Pain—Sunitinib—kidney cancer	0.000574	0.00253	CcSEcCtD
Tolterodine—Gastrointestinal pain—Sorafenib—kidney cancer	0.00057	0.00251	CcSEcCtD
Tolterodine—Anaphylactic shock—Vincristine—kidney cancer	0.000567	0.0025	CcSEcCtD
Tolterodine—Oedema—Vincristine—kidney cancer	0.000567	0.0025	CcSEcCtD
Tolterodine—Infection—Vincristine—kidney cancer	0.000564	0.00248	CcSEcCtD
Tolterodine—Urinary tract infection—Capecitabine—kidney cancer	0.000564	0.00248	CcSEcCtD
Tolterodine—Chest pain—Gemcitabine—kidney cancer	0.000562	0.00247	CcSEcCtD
Tolterodine—Arthralgia—Gemcitabine—kidney cancer	0.000562	0.00247	CcSEcCtD
Tolterodine—Asthenia—Erlotinib—kidney cancer	0.000556	0.00245	CcSEcCtD
Tolterodine—Diarrhoea—Vinblastine—kidney cancer	0.000552	0.00243	CcSEcCtD
Tolterodine—Abdominal pain—Sorafenib—kidney cancer	0.000551	0.00243	CcSEcCtD
Tolterodine—Diarrhoea—Everolimus—kidney cancer	0.00055	0.00242	CcSEcCtD
Tolterodine—Gastrointestinal pain—Sunitinib—kidney cancer	0.000549	0.00242	CcSEcCtD
Tolterodine—Fatigue—Dactinomycin—kidney cancer	0.000548	0.00241	CcSEcCtD
Tolterodine—Flatulence—Paclitaxel—kidney cancer	0.000544	0.0024	CcSEcCtD
Tolterodine—Pain—Dactinomycin—kidney cancer	0.000543	0.00239	CcSEcCtD
Tolterodine—Anaphylactic shock—Gemcitabine—kidney cancer	0.000538	0.00237	CcSEcCtD
Tolterodine—Oedema—Gemcitabine—kidney cancer	0.000538	0.00237	CcSEcCtD
Tolterodine—Infection—Gemcitabine—kidney cancer	0.000535	0.00235	CcSEcCtD
Tolterodine—Dizziness—Vinblastine—kidney cancer	0.000533	0.00235	CcSEcCtD
Tolterodine—Dizziness—Everolimus—kidney cancer	0.000531	0.00234	CcSEcCtD
Tolterodine—Abdominal pain—Sunitinib—kidney cancer	0.00053	0.00233	CcSEcCtD
Tolterodine—Diarrhoea—Erlotinib—kidney cancer	0.00053	0.00233	CcSEcCtD
Tolterodine—Feeling abnormal—Dactinomycin—kidney cancer	0.000523	0.0023	CcSEcCtD
Tolterodine—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000519	0.00229	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000517	0.00228	CcSEcCtD
Tolterodine—Hypersensitivity—Sorafenib—kidney cancer	0.000514	0.00226	CcSEcCtD
Tolterodine—Oedema peripheral—Capecitabine—kidney cancer	0.000513	0.00226	CcSEcCtD
Tolterodine—Dizziness—Erlotinib—kidney cancer	0.000512	0.00226	CcSEcCtD
Tolterodine—Headache—Vinblastine—kidney cancer	0.000505	0.00222	CcSEcCtD
Tolterodine—Angioedema—Paclitaxel—kidney cancer	0.000505	0.00222	CcSEcCtD
Tolterodine—Headache—Everolimus—kidney cancer	0.000503	0.00222	CcSEcCtD
Tolterodine—Abdominal pain—Dactinomycin—kidney cancer	0.000502	0.00221	CcSEcCtD
Tolterodine—Visual impairment—Capecitabine—kidney cancer	0.000502	0.00221	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.000501	0.00221	CcSEcCtD
Tolterodine—Asthenia—Sorafenib—kidney cancer	0.0005	0.0022	CcSEcCtD
Tolterodine—Vertigo—Paclitaxel—kidney cancer	0.000496	0.00218	CcSEcCtD
Tolterodine—Hypersensitivity—Sunitinib—kidney cancer	0.000494	0.00218	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.00049	0.00216	CcSEcCtD
Tolterodine—Fatigue—Vincristine—kidney cancer	0.000489	0.00215	CcSEcCtD
Tolterodine—Palpitations—Paclitaxel—kidney cancer	0.000488	0.00215	CcSEcCtD
Tolterodine—Headache—Erlotinib—kidney cancer	0.000485	0.00214	CcSEcCtD
Tolterodine—Pain—Vincristine—kidney cancer	0.000485	0.00214	CcSEcCtD
Tolterodine—Constipation—Vincristine—kidney cancer	0.000485	0.00214	CcSEcCtD
Tolterodine—Flushing—Capecitabine—kidney cancer	0.000483	0.00213	CcSEcCtD
Tolterodine—Asthenia—Sunitinib—kidney cancer	0.000481	0.00212	CcSEcCtD
Tolterodine—Somnolence—Gemcitabine—kidney cancer	0.000479	0.00211	CcSEcCtD
Tolterodine—Diarrhoea—Sorafenib—kidney cancer	0.000477	0.0021	CcSEcCtD
Tolterodine—Arthralgia—Paclitaxel—kidney cancer	0.00047	0.00207	CcSEcCtD
Tolterodine—Chest pain—Paclitaxel—kidney cancer	0.00047	0.00207	CcSEcCtD
Tolterodine—Anxiety—Paclitaxel—kidney cancer	0.000469	0.00206	CcSEcCtD
Tolterodine—Hypersensitivity—Dactinomycin—kidney cancer	0.000468	0.00206	CcSEcCtD
Tolterodine—Fatigue—Gemcitabine—kidney cancer	0.000464	0.00204	CcSEcCtD
Tolterodine—Gastrointestinal pain—Vincristine—kidney cancer	0.000464	0.00204	CcSEcCtD
Tolterodine—Dizziness—Sorafenib—kidney cancer	0.000461	0.00203	CcSEcCtD
Tolterodine—Constipation—Gemcitabine—kidney cancer	0.00046	0.00203	CcSEcCtD
Tolterodine—Pain—Gemcitabine—kidney cancer	0.00046	0.00203	CcSEcCtD
Tolterodine—Dry mouth—Paclitaxel—kidney cancer	0.00046	0.00202	CcSEcCtD
Tolterodine—Diarrhoea—Sunitinib—kidney cancer	0.000459	0.00202	CcSEcCtD
Tolterodine—Asthenia—Dactinomycin—kidney cancer	0.000456	0.00201	CcSEcCtD
Tolterodine—Confusional state—Paclitaxel—kidney cancer	0.000454	0.002	CcSEcCtD
Tolterodine—Anaphylactic shock—Paclitaxel—kidney cancer	0.000451	0.00198	CcSEcCtD
Tolterodine—Oedema—Paclitaxel—kidney cancer	0.000451	0.00198	CcSEcCtD
Tolterodine—Abdominal pain—Vincristine—kidney cancer	0.000449	0.00197	CcSEcCtD
Tolterodine—Infection—Paclitaxel—kidney cancer	0.000448	0.00197	CcSEcCtD
Tolterodine—Flatulence—Capecitabine—kidney cancer	0.000447	0.00197	CcSEcCtD
Tolterodine—Dry skin—Doxorubicin—kidney cancer	0.000445	0.00196	CcSEcCtD
Tolterodine—Dizziness—Sunitinib—kidney cancer	0.000444	0.00195	CcSEcCtD
Tolterodine—Feeling abnormal—Gemcitabine—kidney cancer	0.000444	0.00195	CcSEcCtD
Tolterodine—Tachycardia—Paclitaxel—kidney cancer	0.00044	0.00194	CcSEcCtD
Tolterodine—Headache—Sorafenib—kidney cancer	0.000437	0.00192	CcSEcCtD
Tolterodine—Diarrhoea—Dactinomycin—kidney cancer	0.000435	0.00191	CcSEcCtD
Tolterodine—Headache—Sunitinib—kidney cancer	0.00042	0.00185	CcSEcCtD
Tolterodine—Hypersensitivity—Vincristine—kidney cancer	0.000418	0.00184	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000411	0.00181	CcSEcCtD
Tolterodine—Vertigo—Capecitabine—kidney cancer	0.000407	0.00179	CcSEcCtD
Tolterodine—Asthenia—Vincristine—kidney cancer	0.000407	0.00179	CcSEcCtD
Tolterodine—Bronchitis—Doxorubicin—kidney cancer	0.000403	0.00178	CcSEcCtD
Tolterodine—Somnolence—Paclitaxel—kidney cancer	0.000401	0.00176	CcSEcCtD
Tolterodine—Palpitations—Capecitabine—kidney cancer	0.0004	0.00176	CcSEcCtD
Tolterodine—Dyspepsia—Paclitaxel—kidney cancer	0.000397	0.00175	CcSEcCtD
Tolterodine—Dysuria—Doxorubicin—kidney cancer	0.000392	0.00173	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.00039	0.00172	CcSEcCtD
Tolterodine—Fatigue—Paclitaxel—kidney cancer	0.000389	0.00171	CcSEcCtD
Tolterodine—Diarrhoea—Vincristine—kidney cancer	0.000388	0.00171	CcSEcCtD
Tolterodine—Asthenia—Gemcitabine—kidney cancer	0.000386	0.0017	CcSEcCtD
Tolterodine—Arthralgia—Capecitabine—kidney cancer	0.000386	0.0017	CcSEcCtD
Tolterodine—Chest pain—Capecitabine—kidney cancer	0.000386	0.0017	CcSEcCtD
Tolterodine—Pain—Paclitaxel—kidney cancer	0.000385	0.0017	CcSEcCtD
Tolterodine—Constipation—Paclitaxel—kidney cancer	0.000385	0.0017	CcSEcCtD
Tolterodine—Anxiety—Capecitabine—kidney cancer	0.000384	0.00169	CcSEcCtD
Tolterodine—Weight increased—Doxorubicin—kidney cancer	0.000382	0.00168	CcSEcCtD
Tolterodine—Dry mouth—Capecitabine—kidney cancer	0.000377	0.00166	CcSEcCtD
Tolterodine—Dizziness—Vincristine—kidney cancer	0.000375	0.00165	CcSEcCtD
Tolterodine—Confusional state—Capecitabine—kidney cancer	0.000373	0.00164	CcSEcCtD
Tolterodine—Feeling abnormal—Paclitaxel—kidney cancer	0.000371	0.00164	CcSEcCtD
Tolterodine—Oedema—Capecitabine—kidney cancer	0.00037	0.00163	CcSEcCtD
Tolterodine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000369	0.00162	CcSEcCtD
Tolterodine—Diarrhoea—Gemcitabine—kidney cancer	0.000368	0.00162	CcSEcCtD
Tolterodine—Infection—Capecitabine—kidney cancer	0.000367	0.00162	CcSEcCtD
Tolterodine—Urinary tract infection—Doxorubicin—kidney cancer	0.000363	0.0016	CcSEcCtD
Tolterodine—Tachycardia—Capecitabine—kidney cancer	0.000361	0.00159	CcSEcCtD
Tolterodine—Abdominal pain—Paclitaxel—kidney cancer	0.000356	0.00157	CcSEcCtD
Tolterodine—Headache—Vincristine—kidney cancer	0.000355	0.00157	CcSEcCtD
Tolterodine—Sinusitis—Doxorubicin—kidney cancer	0.000351	0.00154	CcSEcCtD
Tolterodine—Headache—Gemcitabine—kidney cancer	0.000337	0.00148	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000337	0.00148	CcSEcCtD
Tolterodine—Hypersensitivity—Paclitaxel—kidney cancer	0.000332	0.00146	CcSEcCtD
Tolterodine—Oedema peripheral—Doxorubicin—kidney cancer	0.000331	0.00146	CcSEcCtD
Tolterodine—Dyspepsia—Capecitabine—kidney cancer	0.000326	0.00143	CcSEcCtD
Tolterodine—Visual impairment—Doxorubicin—kidney cancer	0.000323	0.00142	CcSEcCtD
Tolterodine—Asthenia—Paclitaxel—kidney cancer	0.000323	0.00142	CcSEcCtD
Tolterodine—Fatigue—Capecitabine—kidney cancer	0.000319	0.0014	CcSEcCtD
Tolterodine—Constipation—Capecitabine—kidney cancer	0.000316	0.00139	CcSEcCtD
Tolterodine—Pain—Capecitabine—kidney cancer	0.000316	0.00139	CcSEcCtD
Tolterodine—Flushing—Doxorubicin—kidney cancer	0.000311	0.00137	CcSEcCtD
Tolterodine—Diarrhoea—Paclitaxel—kidney cancer	0.000308	0.00136	CcSEcCtD
Tolterodine—Feeling abnormal—Capecitabine—kidney cancer	0.000305	0.00134	CcSEcCtD
Tolterodine—Gastrointestinal pain—Capecitabine—kidney cancer	0.000302	0.00133	CcSEcCtD
Tolterodine—Dizziness—Paclitaxel—kidney cancer	0.000298	0.00131	CcSEcCtD
Tolterodine—Abdominal pain—Capecitabine—kidney cancer	0.000292	0.00129	CcSEcCtD
Tolterodine—Flatulence—Doxorubicin—kidney cancer	0.000288	0.00127	CcSEcCtD
Tolterodine—Headache—Paclitaxel—kidney cancer	0.000282	0.00124	CcSEcCtD
Tolterodine—Hypersensitivity—Capecitabine—kidney cancer	0.000272	0.0012	CcSEcCtD
Tolterodine—Asthenia—Capecitabine—kidney cancer	0.000265	0.00117	CcSEcCtD
Tolterodine—Vertigo—Doxorubicin—kidney cancer	0.000262	0.00116	CcSEcCtD
Tolterodine—Palpitations—Doxorubicin—kidney cancer	0.000258	0.00114	CcSEcCtD
Tolterodine—Diarrhoea—Capecitabine—kidney cancer	0.000253	0.00111	CcSEcCtD
Tolterodine—Arthralgia—Doxorubicin—kidney cancer	0.000249	0.00109	CcSEcCtD
Tolterodine—Chest pain—Doxorubicin—kidney cancer	0.000249	0.00109	CcSEcCtD
Tolterodine—Anxiety—Doxorubicin—kidney cancer	0.000248	0.00109	CcSEcCtD
Tolterodine—Dizziness—Capecitabine—kidney cancer	0.000245	0.00108	CcSEcCtD
Tolterodine—Dry mouth—Doxorubicin—kidney cancer	0.000243	0.00107	CcSEcCtD
Tolterodine—Confusional state—Doxorubicin—kidney cancer	0.00024	0.00106	CcSEcCtD
Tolterodine—Anaphylactic shock—Doxorubicin—kidney cancer	0.000238	0.00105	CcSEcCtD
Tolterodine—Oedema—Doxorubicin—kidney cancer	0.000238	0.00105	CcSEcCtD
Tolterodine—Infection—Doxorubicin—kidney cancer	0.000237	0.00104	CcSEcCtD
Tolterodine—Tachycardia—Doxorubicin—kidney cancer	0.000233	0.00102	CcSEcCtD
Tolterodine—Headache—Capecitabine—kidney cancer	0.000232	0.00102	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000217	0.000956	CcSEcCtD
Tolterodine—Somnolence—Doxorubicin—kidney cancer	0.000212	0.000933	CcSEcCtD
Tolterodine—Dyspepsia—Doxorubicin—kidney cancer	0.00021	0.000924	CcSEcCtD
Tolterodine—Fatigue—Doxorubicin—kidney cancer	0.000206	0.000905	CcSEcCtD
Tolterodine—Constipation—Doxorubicin—kidney cancer	0.000204	0.000898	CcSEcCtD
Tolterodine—Pain—Doxorubicin—kidney cancer	0.000204	0.000898	CcSEcCtD
Tolterodine—Feeling abnormal—Doxorubicin—kidney cancer	0.000196	0.000865	CcSEcCtD
Tolterodine—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000195	0.000858	CcSEcCtD
Tolterodine—Abdominal pain—Doxorubicin—kidney cancer	0.000188	0.00083	CcSEcCtD
Tolterodine—Hypersensitivity—Doxorubicin—kidney cancer	0.000176	0.000773	CcSEcCtD
Tolterodine—Asthenia—Doxorubicin—kidney cancer	0.000171	0.000753	CcSEcCtD
Tolterodine—Diarrhoea—Doxorubicin—kidney cancer	0.000163	0.000718	CcSEcCtD
Tolterodine—Dizziness—Doxorubicin—kidney cancer	0.000158	0.000694	CcSEcCtD
Tolterodine—Headache—Doxorubicin—kidney cancer	0.000149	0.000658	CcSEcCtD
Tolterodine—CHRM3—Metabolism—ABCB1—kidney cancer	9.34e-06	0.000312	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ITPR2—kidney cancer	9.33e-06	0.000312	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTT1—kidney cancer	9.25e-06	0.000309	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ACHE—kidney cancer	9.25e-06	0.000309	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ITPR2—kidney cancer	9.25e-06	0.000309	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—HIF1A—kidney cancer	9.1e-06	0.000304	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—POMC—kidney cancer	9.1e-06	0.000304	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—KDR—kidney cancer	9.09e-06	0.000304	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TSC2—kidney cancer	9.08e-06	0.000303	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC5A3—kidney cancer	9.08e-06	0.000303	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PGK1—kidney cancer	9.08e-06	0.000303	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—POMC—kidney cancer	9.07e-06	0.000303	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—GSTM1—kidney cancer	9.07e-06	0.000303	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—POMC—kidney cancer	8.98e-06	0.0003	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—LDHB—kidney cancer	8.9e-06	0.000297	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—SCARB1—kidney cancer	8.76e-06	0.000292	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—KDR—kidney cancer	8.71e-06	0.000291	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTGS1—kidney cancer	8.67e-06	0.00029	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CYP1A1—kidney cancer	8.6e-06	0.000287	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	8.53e-06	0.000285	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTT1—kidney cancer	8.51e-06	0.000284	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ACHE—kidney cancer	8.51e-06	0.000284	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PSMD7—kidney cancer	8.5e-06	0.000284	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTT1—kidney cancer	8.44e-06	0.000282	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ACHE—kidney cancer	8.44e-06	0.000282	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—KIT—kidney cancer	8.38e-06	0.00028	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—APC—kidney cancer	8.38e-06	0.00028	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—BCHE—kidney cancer	8.06e-06	0.000269	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—SCARB1—kidney cancer	8.06e-06	0.000269	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IGF2—kidney cancer	8.05e-06	0.000269	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IGF2—kidney cancer	8.03e-06	0.000268	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—MAPK3—kidney cancer	8.02e-06	0.000268	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—APC—kidney cancer	8.02e-06	0.000268	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—KIT—kidney cancer	8.02e-06	0.000268	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CDKN2B—kidney cancer	8.02e-06	0.000268	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CDKN2B—kidney cancer	7.99e-06	0.000267	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—SCARB1—kidney cancer	7.99e-06	0.000267	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTGS1—kidney cancer	7.98e-06	0.000266	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—POMC—kidney cancer	7.97e-06	0.000266	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—SLC5A5—kidney cancer	7.96e-06	0.000266	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IGF2—kidney cancer	7.95e-06	0.000265	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CDKN2B—kidney cancer	7.92e-06	0.000264	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTGS1—kidney cancer	7.91e-06	0.000264	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—BRAF—kidney cancer	7.87e-06	0.000263	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PSMD7—kidney cancer	7.82e-06	0.000261	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IGF1R—kidney cancer	7.79e-06	0.00026	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IGF1R—kidney cancer	7.76e-06	0.000259	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PSMD7—kidney cancer	7.75e-06	0.000259	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CA9—kidney cancer	7.72e-06	0.000258	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—SLC2A1—kidney cancer	7.69e-06	0.000257	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IGF1R—kidney cancer	7.69e-06	0.000257	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—MAPK3—kidney cancer	7.68e-06	0.000256	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—POMC—kidney cancer	7.64e-06	0.000255	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—MAPK1—kidney cancer	7.63e-06	0.000255	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—BRAF—kidney cancer	7.54e-06	0.000252	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—RAF1—kidney cancer	7.5e-06	0.000251	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—RAF1—kidney cancer	7.48e-06	0.00025	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	7.46e-06	0.000249	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—BCHE—kidney cancer	7.42e-06	0.000248	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—IL2—kidney cancer	7.41e-06	0.000247	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—RAF1—kidney cancer	7.41e-06	0.000247	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—IL2—kidney cancer	7.39e-06	0.000247	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—BCHE—kidney cancer	7.35e-06	0.000245	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—SLC5A5—kidney cancer	7.32e-06	0.000245	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—IL2—kidney cancer	7.31e-06	0.000244	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—MAPK1—kidney cancer	7.31e-06	0.000244	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—PIK3CA—kidney cancer	7.29e-06	0.000244	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—SLC5A5—kidney cancer	7.26e-06	0.000242	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—KRAS—kidney cancer	7.21e-06	0.000241	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—SLC2A1—kidney cancer	7.07e-06	0.000236	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—SLC2A1—kidney cancer	7.01e-06	0.000234	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—PIK3CA—kidney cancer	6.98e-06	0.000233	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—KRAS—kidney cancer	6.9e-06	0.000231	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	6.8e-06	0.000227	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—IL2—kidney cancer	6.73e-06	0.000225	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL2—kidney cancer	6.71e-06	0.000224	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—IL2—kidney cancer	6.64e-06	0.000222	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—PIK3CA—kidney cancer	6.62e-06	0.000221	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—RAF1—kidney cancer	6.57e-06	0.000219	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CRABP1—kidney cancer	6.56e-06	0.000219	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—RELA—kidney cancer	6.54e-06	0.000219	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	6.51e-06	0.000217	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—ERBB2—kidney cancer	6.5e-06	0.000217	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MTOR—kidney cancer	6.42e-06	0.000214	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTP1—kidney cancer	6.41e-06	0.000214	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HIF1A—kidney cancer	6.41e-06	0.000214	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—POMC—kidney cancer	6.41e-06	0.000214	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TSC2—kidney cancer	6.39e-06	0.000214	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HIF1A—kidney cancer	6.39e-06	0.000213	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TSC2—kidney cancer	6.37e-06	0.000213	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—PIK3CA—kidney cancer	6.34e-06	0.000212	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HIF1A—kidney cancer	6.33e-06	0.000211	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TSC2—kidney cancer	6.31e-06	0.000211	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—RAF1—kidney cancer	6.3e-06	0.00021	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—RELA—kidney cancer	6.27e-06	0.000209	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—ERBB2—kidney cancer	6.23e-06	0.000208	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MTOR—kidney cancer	6.15e-06	0.000205	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KDR—kidney cancer	6.13e-06	0.000205	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KDR—kidney cancer	6.11e-06	0.000204	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ITPR2—kidney cancer	6.1e-06	0.000204	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ABCB1—kidney cancer	6.07e-06	0.000203	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KDR—kidney cancer	6.05e-06	0.000202	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CDKN1B—kidney cancer	6.02e-06	0.000201	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.93e-06	0.000198	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTP1—kidney cancer	5.9e-06	0.000197	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTM1—kidney cancer	5.89e-06	0.000197	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IL2—kidney cancer	5.89e-06	0.000197	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTP1—kidney cancer	5.85e-06	0.000195	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CDKN1B—kidney cancer	5.77e-06	0.000193	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCND1—kidney cancer	5.75e-06	0.000192	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—JUN—kidney cancer	5.73e-06	0.000191	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CTNNB1—kidney cancer	5.69e-06	0.00019	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KIT—kidney cancer	5.65e-06	0.000189	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—APC—kidney cancer	5.65e-06	0.000189	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL2—kidney cancer	5.64e-06	0.000188	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KIT—kidney cancer	5.63e-06	0.000188	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—APC—kidney cancer	5.63e-06	0.000188	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CYP1A1—kidney cancer	5.59e-06	0.000187	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ABCB1—kidney cancer	5.58e-06	0.000186	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KIT—kidney cancer	5.58e-06	0.000186	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—APC—kidney cancer	5.58e-06	0.000186	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ACHE—kidney cancer	5.57e-06	0.000186	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTT1—kidney cancer	5.57e-06	0.000186	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PTEN—kidney cancer	5.55e-06	0.000185	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ABCB1—kidney cancer	5.54e-06	0.000185	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCND1—kidney cancer	5.5e-06	0.000184	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—JUN—kidney cancer	5.49e-06	0.000183	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CTNNB1—kidney cancer	5.45e-06	0.000182	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTM1—kidney cancer	5.42e-06	0.000181	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—MAPK3—kidney cancer	5.41e-06	0.000181	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—MAPK3—kidney cancer	5.39e-06	0.00018	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—POMC—kidney cancer	5.38e-06	0.000179	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTM1—kidney cancer	5.37e-06	0.000179	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—POMC—kidney cancer	5.36e-06	0.000179	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—MAPK3—kidney cancer	5.34e-06	0.000178	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PTEN—kidney cancer	5.31e-06	0.000177	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—BRAF—kidney cancer	5.31e-06	0.000177	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—POMC—kidney cancer	5.31e-06	0.000177	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—BRAF—kidney cancer	5.29e-06	0.000177	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SCARB1—kidney cancer	5.27e-06	0.000176	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—BRAF—kidney cancer	5.24e-06	0.000175	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS1—kidney cancer	5.21e-06	0.000174	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—MAPK1—kidney cancer	5.15e-06	0.000172	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CYP1A1—kidney cancer	5.14e-06	0.000172	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—MAPK1—kidney cancer	5.13e-06	0.000171	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PSMD7—kidney cancer	5.11e-06	0.000171	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTGS2—kidney cancer	5.11e-06	0.000171	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CYP1A1—kidney cancer	5.1e-06	0.00017	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—MAPK1—kidney cancer	5.08e-06	0.00017	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—VEGFA—kidney cancer	5.01e-06	0.000167	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—PIK3CA—kidney cancer	4.92e-06	0.000164	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—PIK3CA—kidney cancer	4.9e-06	0.000164	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—KRAS—kidney cancer	4.86e-06	0.000162	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—PIK3CA—kidney cancer	4.85e-06	0.000162	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—BCHE—kidney cancer	4.85e-06	0.000162	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—KRAS—kidney cancer	4.85e-06	0.000162	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—KRAS—kidney cancer	4.8e-06	0.00016	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—VEGFA—kidney cancer	4.8e-06	0.00016	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC5A5—kidney cancer	4.79e-06	0.00016	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MAPK3—kidney cancer	4.74e-06	0.000158	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC2A1—kidney cancer	4.62e-06	0.000154	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MYC—kidney cancer	4.61e-06	0.000154	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.59e-06	0.000153	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MAPK3—kidney cancer	4.54e-06	0.000152	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MAPK1—kidney cancer	4.51e-06	0.000151	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—PIK3CA—kidney cancer	4.47e-06	0.000149	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTEN—kidney cancer	4.46e-06	0.000149	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—PIK3CA—kidney cancer	4.45e-06	0.000149	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—RAF1—kidney cancer	4.43e-06	0.000148	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—RAF1—kidney cancer	4.42e-06	0.000148	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MYC—kidney cancer	4.41e-06	0.000147	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—RELA—kidney cancer	4.41e-06	0.000147	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—PIK3CA—kidney cancer	4.41e-06	0.000147	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—RELA—kidney cancer	4.4e-06	0.000147	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ERBB2—kidney cancer	4.39e-06	0.000146	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—RAF1—kidney cancer	4.38e-06	0.000146	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ERBB2—kidney cancer	4.37e-06	0.000146	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—RELA—kidney cancer	4.36e-06	0.000145	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ERBB2—kidney cancer	4.33e-06	0.000145	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MTOR—kidney cancer	4.33e-06	0.000144	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MAPK1—kidney cancer	4.32e-06	0.000144	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MTOR—kidney cancer	4.31e-06	0.000144	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MTOR—kidney cancer	4.27e-06	0.000143	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—KRAS—kidney cancer	4.26e-06	0.000142	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.19e-06	0.00014	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—POMC—kidney cancer	4.17e-06	0.000139	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—KRAS—kidney cancer	4.08e-06	0.000136	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CDKN1B—kidney cancer	4.06e-06	0.000136	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CDKN1B—kidney cancer	4.05e-06	0.000135	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CDKN1B—kidney cancer	4.01e-06	0.000134	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL2—kidney cancer	3.97e-06	0.000133	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL2—kidney cancer	3.96e-06	0.000132	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL2—kidney cancer	3.92e-06	0.000131	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PIK3CA—kidney cancer	3.91e-06	0.000131	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCND1—kidney cancer	3.87e-06	0.000129	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—JUN—kidney cancer	3.87e-06	0.000129	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCND1—kidney cancer	3.86e-06	0.000129	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTP1—kidney cancer	3.86e-06	0.000129	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—JUN—kidney cancer	3.85e-06	0.000129	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CTNNB1—kidney cancer	3.84e-06	0.000128	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—POMC—kidney cancer	3.83e-06	0.000128	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCND1—kidney cancer	3.82e-06	0.000128	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CTNNB1—kidney cancer	3.82e-06	0.000128	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—JUN—kidney cancer	3.82e-06	0.000127	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—POMC—kidney cancer	3.8e-06	0.000127	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CTNNB1—kidney cancer	3.79e-06	0.000126	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TP53—kidney cancer	3.79e-06	0.000126	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PIK3CA—kidney cancer	3.75e-06	0.000125	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PTEN—kidney cancer	3.74e-06	0.000125	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PTEN—kidney cancer	3.73e-06	0.000124	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PTEN—kidney cancer	3.69e-06	0.000123	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ABCB1—kidney cancer	3.65e-06	0.000122	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TP53—kidney cancer	3.62e-06	0.000121	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTM1—kidney cancer	3.54e-06	0.000118	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—VEGFA—kidney cancer	3.38e-06	0.000113	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—VEGFA—kidney cancer	3.37e-06	0.000112	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP1A1—kidney cancer	3.36e-06	0.000112	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—VEGFA—kidney cancer	3.33e-06	0.000111	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTGS2—kidney cancer	3.32e-06	0.000111	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAPK3—kidney cancer	3.2e-06	0.000107	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAPK3—kidney cancer	3.19e-06	0.000106	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAPK3—kidney cancer	3.15e-06	0.000105	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CA—kidney cancer	3.15e-06	0.000105	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MYC—kidney cancer	3.11e-06	0.000104	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MYC—kidney cancer	3.1e-06	0.000103	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MYC—kidney cancer	3.07e-06	0.000102	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTGS2—kidney cancer	3.06e-06	0.000102	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAPK1—kidney cancer	3.04e-06	0.000102	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAPK1—kidney cancer	3.03e-06	0.000101	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTGS2—kidney cancer	3.03e-06	0.000101	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAPK1—kidney cancer	3e-06	0.0001	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTEN—kidney cancer	2.9e-06	9.68e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KRAS—kidney cancer	2.87e-06	9.59e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KRAS—kidney cancer	2.86e-06	9.56e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KRAS—kidney cancer	2.83e-06	9.46e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTEN—kidney cancer	2.67e-06	8.9e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTEN—kidney cancer	2.64e-06	8.82e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CA—kidney cancer	2.64e-06	8.81e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CA—kidney cancer	2.63e-06	8.78e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CA—kidney cancer	2.6e-06	8.7e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TP53—kidney cancer	2.55e-06	8.52e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TP53—kidney cancer	2.54e-06	8.49e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TP53—kidney cancer	2.52e-06	8.41e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—POMC—kidney cancer	2.51e-06	8.37e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CA—kidney cancer	2.04e-06	6.83e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS2—kidney cancer	2e-06	6.67e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.88e-06	6.28e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.86e-06	6.22e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTEN—kidney cancer	1.74e-06	5.82e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.23e-06	4.11e-05	CbGpPWpGaD
